Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Jul;139(7):1157-67.
doi: 10.1007/s00432-013-1425-1. Epub 2013 Apr 4.

High circulating VEGF level predicts poor overall survival in lung cancer

Pingping Hu  1 , Weidong Liu, Liguang Wang, Miaomiao Yang, Jiajun Du
Affiliations
Meta-Analysis

High circulating VEGF level predicts poor overall survival in lung cancer

Pingping Hu et al. J Cancer Res Clin Oncol. 2013 Jul.

Abstract

Purpose: Vascular endothelial growth factor (VEGF) is considered as the best-validated key regulator of angiogenesis, while the prognostic role of circulating VEGF in lung cancer remains controversial. We conducted a meta-analysis to evaluate the prognostic role of circulating VEGF.

Methods: Nineteen studies with a total number of 2,890 patients were analyzed in our meta-analysis. Hazard ratios (HRs) and their 95 % confidence intervals (CIs) were used to quantify the predictive ability of circulating VEGF on survival.

Results: The pooled HR of all 17 studies evaluating overall survival (OS) was 1.29 (95 % CI 1.19-1.40, p < 0.001), indicating high circulating VEGF predicted poor OS. When grouped by disease stages, the pooled HRs were 0.97 (95 % CI 0.47-1.47, p < 0.001) for operable stage and 1.34 (95 % CI 1.18-1.49, p < 0.001) for inoperable stage. The pooled HRs were 1.28 (95 % CI 1.15-1.42, p < 0.001) for serum and 1.31 (95 % CI 1.13-1.49, p < 0.001) for plasma, when categorized by blood sample. Meta-analysis of circulating VEGF related to progression-free survival (PFS) was performed in 7 studies, and the pooled HR was 1.03 (95 % CI 0.96-1.09).

Conclusions: Our results indicate that high level of circulating VEGF predicts poor OS in lung cancer, yet it does not predict poor PFS.

PubMed Disclaimer

Conflict of interest statement

The authors have declared no conflicts of interest.

Figures

Fig. 1
Fig. 1
Flow diagram of the meta-analysis
Fig. 2
Fig. 2
a Forrest plot to assess the overall effect of circulating VEGF on OS. b Forrest plot to assess the overall effect of circulating VEGF on PFS
Fig. 3
Fig. 3
Forrest plots of sub-groups. HRs of operable stage and inoperable stage are reported as (a). HRs of serum and plasma are reported as (b)
See this image and copyright information in PMC

References

    1. Altman DG (2001) Systematic reviews of evaluations of prognostic variables. BMJ 323(7306):224–228 - DOI - PMC - PubMed
    1. An SJ, Huang YS, Chen ZH, Su J, Yang Y, Chen JG, Yan HH, Lin QX, Yang JJ, Yang XN, Zhou Q, Zhang XC, Wu YL (2012) Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Med Oncol 29(2):627–632. doi:10.1007/s12032-011-9924-x - DOI - PubMed
    1. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410 - DOI - PubMed
    1. Brattstrom D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O, Wagenius G (1998) Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 18(2A):1123–1127 - PubMed
    1. Brattstrom D, Bergqvist M, Hesselius P, Larsson A, Lamberg K, Wernlund J, Brodin O, Wagenius G (2002) Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 37(1):57–63 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources